Literature DB >> 16997559

5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase.

Paul Bamborough1, John A Christopher, Geoffrey J Cutler, Marion C Dickson, Geoffrey W Mellor, James V Morey, Champa B Patel, Lisa M Shewchuk.   

Abstract

The identification and hit-to-lead exploration of a novel, potent and selective series of substituted benzimidazole-thiophene carbonitrile inhibitors of IKK-epsilon kinase is described. Compound 12e was identified with an IKK-epsilon enzyme potency of pIC(50) 7.4, and has a highly encouraging wider selectivity profile, including selectivity within the IKK kinase family.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16997559     DOI: 10.1016/j.bmcl.2006.09.018

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

1.  Autophagy-Independent Lysosomal Targeting Regulated by ULK1/2-FIP200 and ATG9.

Authors:  Jonathan M Goodwin; William E Dowdle; Rowena DeJesus; Zuncai Wang; Philip Bergman; Marek Kobylarz; Alicia Lindeman; Ramnik J Xavier; Gregory McAllister; Beat Nyfeler; Gregory Hoffman; Leon O Murphy
Journal:  Cell Rep       Date:  2017-09-05       Impact factor: 9.423

2.  Selective TBK1/IKKi dual inhibitors with anticancer potency.

Authors:  Jijia Li; Jingjia Huang; Ji-Hak Jeong; Sun-Jin Park; Rui Wei; Jieying Peng; Zhiyong Luo; Yen Ting Chen; Yangbo Feng; Jun-Li Luo
Journal:  Int J Cancer       Date:  2013-10-21       Impact factor: 7.396

3.  Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells.

Authors:  Chao Zhang; Xiaodong Sun; Yuan Ren; Yunbo Lou; Jun Zhou; Min Liu; Dengwen Li
Journal:  Cancer Biol Ther       Date:  2012-08-15       Impact factor: 4.742

4.  TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation.

Authors:  Yi-Hung Ou; Michael Torres; Rosalyn Ram; Etienne Formstecher; Christina Roland; Tzuling Cheng; Rolf Brekken; Ryan Wurz; Andrew Tasker; Tony Polverino; Seng-Lai Tan; Michael A White
Journal:  Mol Cell       Date:  2011-02-18       Impact factor: 17.970

5.  From PIM1 to PI3Kδ via GSK3β: Target Hopping through the Kinome.

Authors:  Zoë A Henley; Benjamin D Bax; Laura M Inglesby; Aurélie Champigny; Simon Gaines; Paul Faulder; Joelle Le; Daniel A Thomas; Yoshiaki Washio; Ian R Baldwin
Journal:  ACS Med Chem Lett       Date:  2017-09-07       Impact factor: 4.345

6.  Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.

Authors:  Stefanie A Hartsink-Segers; Carla Exalto; Matthew Allen; Daniel Williamson; Steven C Clifford; Martin Horstmann; Huib N Caron; Rob Pieters; Monique L Den Boer
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

7.  Benzimidazole inhibitors of the protein kinase CHK2: clarification of the binding mode by flexible side chain docking and protein-ligand crystallography.

Authors:  Cornelis Matijssen; M Cris Silva-Santisteban; Isaac M Westwood; Samerene Siddique; Vanessa Choi; Peter Sheldrake; Rob L M van Montfort; Julian Blagg
Journal:  Bioorg Med Chem       Date:  2012-09-21       Impact factor: 3.641

8.  The Baf60c/Deptor pathway links skeletal muscle inflammation to glucose homeostasis in obesity.

Authors:  Zhuo-Xian Meng; Lin Wang; Yuanyuan Xiao; Jiandie D Lin
Journal:  Diabetes       Date:  2014-01-23       Impact factor: 9.461

9.  An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.

Authors:  Shannon M Reilly; Shian-Huey Chiang; Stuart J Decker; Louise Chang; Maeran Uhm; Martha J Larsen; John R Rubin; Jonathan Mowers; Nicole M White; Irit Hochberg; Michael Downes; Ruth T Yu; Christopher Liddle; Ronald M Evans; Dayoung Oh; Pingping Li; Jerrold M Olefsky; Alan R Saltiel
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

10.  Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1.

Authors:  Jonathan Mowers; Maeran Uhm; Shannon M Reilly; Joshua Simon; Dara Leto; Shian-Huey Chiang; Louise Chang; Alan R Saltiel
Journal:  Elife       Date:  2013-12-24       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.